anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study aimed to develop, validate, and evaluate machine learning (ML) algorithms for predicting Surgical site infections (SSI) and surgical site occurrences (SSO) after elective open inguinal hernia surgery.
METHODS: A cohort of 491 patients who underwent elective open inguinal hernia surgery at Fudan University Affiliated Huadong Hospital between December 2019 and December 2020 was enrolled. To create a strong prediction model, we employed five ML methods: generalized linear model, random forest (RF), support vector machines, neural network, and gradient boosting machine. Based on the best performing model, we devised online calculators to facilitate clinicians' access to a linear predictor for patients. The receiver operating characteristic curve was utilized to evaluate the model's discriminatory capability and predictive accuracy.
RESULTS: The incidence rates of SSI and SSO were 4.68% and 13.44%, respectively. Four variables (diabetes, recurrence, antibiotic prophylaxis, and duration of surgery) were identified for SSI prediction, while four variables (diabetes, size of hernias, albumin levels, and antibiotic prophylaxis) were included for SSO prediction. In the test set, the RF model showed the best predictive ability (SSI: area under the curve (AUC) = 0.849, sensitivity = 0.769, specificity = 0.769, and accuracy = 0.769; SSO: AUC = 0.740, sensitivity = 0.513, specificity = 0.821, and accuracy = 0.667). Online calculators have been developed to assess patients' risk of SSI ( https://wuqian17.shinyapps.io/predictionSSI/ ) and SSO ( https://wuqian17.shinyapps.io/predictionSSO/ ) after surgery.
CONCLUSIONS: This study developed a prediction model for SSI/SSO using ML methods. It holds the potential to facilitate the selection of appropriate treatment options following elective open inguinal hernia surgery.
Acetaminophen (APAP)-induced liver injury is one of the most frequent causes of acute liver failure worldwide. Significant increases in the levels of miRNA-21 in both liver tissues and plasma have been observed in APAP-overdosed animals and humans. However, the mechanistic effect of miRNA-21 on acute liver injury remains unknown. In this study, we generated a new hepatocyte-specific miRNA-21 knockout (miR-21-HKO) mouse line. miR-21-HKO and the background-matched sibling wild-type (WT) mice were treated with a toxic dose of APAP. Compared with WT mice, miR-21 HKO mice showed an increased survival, a reduction of necrotic hepatocytes, and an increased expression of light chain 3 beta, which suggested an autophagy activation. The expression of PPARγ was highly induced in the livers of miR-21-HKO mice after a 2-h APAP treatment, which preceded the activation of LC3B at the 12 h APAP treatment. miR-21 negatively regulated PPARγ protein expression by targeting its 3'-UTR. When PPARγ function was blocked by a potent antagonist GW9662 in miR-21-HKO mice, the autophage activation was significantly diminished, suggesting an indispensable role of PPARγ signaling pathway in miR-21-mediated hepatotoxicity. Taken together, hepatocyte-specific depletion of miRNA-21 alleviated APAP-induced hepatotoxicity by activating PPARγ and autophagy, demonstrating a crucial new regulatory role of miR-21 in APAP-mediated liver injury.
Asfotase alfa is a tissue nonspecific alkaline phosphatase (TNSALP) produced by recombinant DNA technology in a Chinese hamster ovary cell line. Asfotase alfa is a soluble glycoprotein composed of two identical polypeptide chains. Each chain contains 726 amino acids with a theoretical mass of 161 kDa. Each chain consists of the catalytic domain of human TNSALP, the human immunoglobulin G1 Fc domain and a deca-aspartate peptide used as a bone targeting domain. The two polypeptide chains are covalently linked by two disulfide bonds.

STRENSIQ (asfotase alfa) injection is a sterile, preservative-free, nonpyrogenic, clear, slightly opalescent or opalescent, colorless to slightly yellow, with few small translucent or white particles, aqueous solution for subcutaneous administration. STRENSIQ is supplied in glass single-dose vials containing asfotase alfa; dibasic sodium phosphate, heptahydrate; monobasic sodium phosphate, monohydrate; and sodium chloride at a pH between 7.2 and 7.6. Table 5 describes the content of STRENSIQ vial presentations.
The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
The invention discloses a traditional Chinese medicine composition for treating osteoporosis and kidney deficiency and blood stasis, which is a monarch drug for nourishing liver and kidney, replenishing bones and muscles, regulating blood vessels, and replenishing fracture. Oyster has effects of astringing yin and suppressing yang, arresting sweating and astringing essence, cuttlebone has effects of stopping nocturnal emission and stopping leukorrhagia, relieving hyperacidity and pain, concha Haliotidis has effects of suppressing hyperactive liver and suppressing yang, removing heat, improving eyesight, concha Meretricis Seu Cyclinae has effects of nourishing yin and promoting fluid production, softening hard mass and resolving hard mass, margarita powder has effects of nourishing yin and calming endogenous wind, and clearing heat and eliminating phlegm, and can be used as ministerial drug. The Chinese angelica root, radix Angelicae sinensis has the effects of replenishing blood, activating collaterals, relieving pain, nourishing yin, replenishing blood, and codonopsis pilosula has the effects of invigorating spleen, replenishing qi, harmonizing stomach and promoting fluid production, and is taken as an adjuvant drug. Ligusticum wallichii and rhizoma corydalis have the effects of promoting blood circulation, activating qi-flowing, activating collaterals and relieving pain, and the guiding medicine directly reaches the affected part. Eggshell is used as a guide for strengthening bones and relieving pain. Comprehensively utilizes the advantages and mutual synergistic effect of the medicines, and has the functions of promoting blood circulation, promoting qi circulation, tonifying kidney, calming liver and promoting qi and blood circulation; tonify kidney, strengthen bone, activate blood and promote qi circulation to treat its root cause, pacify liver and subdue yang, unblock collaterals and relieve pain to treat its symptoms. The medicament has the advantages of taking the root into consideration, promoting qi to generate and promoting blood circulation, and has remarkable curative effect on osteoporosis, kidney deficiency and blood stasis.
Chronic kidney disease in patients with HIV-1 infection treated with atazanavir, with or without ritonavir, has been reported during postmarketing surveillance. Reports included biopsy-proven cases of granulomatous interstitial nephritis associated with the deposition of atazanavir drug crystals in the renal parenchyma. Consider alternatives to atazanavir in patients at high risk for renal disease or with preexisting renal disease. Renal laboratory testing (including serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination) should be conducted in all patients prior to initiating therapy with atazanavir and continued during treatment with atazanavir. Expert consultation is advised for patients who have confirmed renal laboratory abnormalities while taking atazanavir. In patients with progressive kidney disease, discontinuation of atazanavir may be considered [ see Dosage and Administration ( 2.2 and 2.7) and Adverse Reactions ( 6.2) ].
BACKGROUND: Prolonged obstructive jaundice (OJ), associated with resectable pancreatic pathology, has many deleterious effects that are potentially rectifiable by preoperative biliary drainage (POBD) at the cost of increased postoperative infective complications. The aim of this study is to assess the impact of POBD on intraoperative biliary cultures (IBCs) and surgical outcomes in patients undergoing pancreatic resection.
METHODS: Data from patients at Groote Schuur Hospital, Cape Town, between October 2008 and May 2019 were analysed. Demographic, clinical, and outcome variables were evaluated, including perioperative morbidity, mortality, and 5-year survival.
RESULTS: Among 128 patients, 69.5% underwent POBD. The overall perioperative mortality in this study was 8.8%. The POBD group had a significantly lower perioperative mortality rate compared to the non-drainage group (5.6% vs. 25.6%). POBD patients had a higher incidence of surgical site infections (55.1% vs. 23.1%), polymicrobial growth from IBCs and were more likely to culture resistant organisms. Five-year survival was similar in the two groups.
CONCLUSION: POBD was associated with a high incidence of resistant organisms on the IBCs, a high incidence of surgical site infections and a high correlation between cultures from the surgical site infection and the IBCs.
A reagent for treating or imaging a cancerous tumor in vivo comprises a carbohydrate having a paramagnetic atom bonded thereto. The carbohydrate is capable of binding or penetrating a cancerous cell. When the reagent is used for imaging, gadolinium comprises one preferred paramagnetic atom. When the reagent is used for applying thermal energy to a tumor, the paramagnetic atom preferably comprises iron. The reagent may be disposed in a carrier, and the carrier may comprise liposomes. The reagent may be used in combination with other diagnostic or therapeutic materials. One preferred material comprises gadolinium glucoside.
PROBLEM TO BE SOLVED: To provide an adhesive pack for protecting ultraviolet(UV) rays capable of being easily used and effective for a long time. SOLUTION: This adhesive pack for protecting UV rays comprises a support 6 and an adhesive base material 1 added with a UV-protecting agent 2 and formed on the support 6 in a layer form. At least one kind selected from materials for enhancing beautifying effects, solubilizing agents and absorption- accelerating agents can further be added to the adhesive base material 1. The base material 1 contains, e.g. water, a surfactant, a polyhydric alcohol, a water soluble polymer and a metal crosslinking agent. As the UV-absorbing agent is absorbed from the skin and remains in a large amount in keratin by adhering the pack on a spot such as face, the back of hand, and the like, for a predetermined time, the protecting effect on the UV-rays remains for a long time even after peeling off the pack.
PROBLEM TO BE SOLVED: To obtain a beauty whitening cosmetic material good in percutaneous absorption of effective ingredients and excellent in a light coloring effect of the skin and an improving effect of stains and freckles caused by sun burn by using a spiro-ether compound having a beauty whitening effect together with a specific additive. SOLUTION: In this beauty whitening cosmetic material, a spiro-ether compound of formula I (a wavy line can be Z or E in its bonding state) is combined with a percutaneous absorbefacient. As the absorbefacient, one or more compounds selected from guanidine derivatives and their acid added salts of formula II or III [A and B are each an alkylene; D is a bond, CO or an alkylene; E is H, an alkyl, an aralkyl or an aryl; (m) is 1-6; (n) is 0-6; R<1> is H, an alkyl, etc.; (l) is 1-10; G is H, OH, COOH, sulfo group or phosphate group] are preferable. And α-monoglyceryl ether urea expressed by formula IV (R<2> is an alkyl or an alkenyl) is also preferable. An ascorbic acid derivative, etc., can be further added to the cosmetic material.
Patients undergo peripheral blood stem cell infusion on day 0. Patients receive cyclophosphamide IV QD on days 3 and 4, itacitinib PO QD on days 5-100, and tacrolimus IV or PO on days 6-65.
Prolongation of prothrombin time occurs in patients stabilized on warfarin.

Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs.

Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs.

Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol.

Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism.

The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvastatin and lovastatin. Caution should be exercised if used concomitantly. Consult the product labeling for statin drugs for specific information on dose restrictions in presence of danazol.
Some people with depression do not respond well to antidepressant treatment. S-adenosyl methionine (SAMe) is a naturally occurring compound that may have antidepressant effects. SAMe may also enhance the effectiveness of other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs). This study will determine the effectiveness of oral SAMe in enhancing the effects of SSRIs in patients currently not responding to SSRI treatment.

This study will last 6 weeks. No follow-up visits will occur. Participants will be randomly assigned to add either oral SAMe or placebo to their existing SSRI regimen for 6 weeks. Depression scales and self-report questionnaires regarding depressive symptoms will be used to assess participants at the end of the study.
PROBLEM TO BE SOLVED: To enable the reduction of the content of the cholesterol in a poultry egg by a new method comprising the use of a cholesterol biosynthesis inhibitor having an isoprenoid structure. SOLUTION: A cholesterol biosynthesis inhibitor having an isoprenoid structure is used. Examples of the inhibitor are tocotrienols of formula I (R1 to R3 are each CH3, R1 and R3 are each CH3 and R2 is H, or the like) and terpenoids. As the terpenoid, a linalool of formula II (R is H or CO-acyl) or the like is preferred. The inhibitor is preferably used by compounding in a conventional feed for poultry. Commonly, it is compounded in an amount of 5-10,000 mg based on 1 kg of the feed. In the case of tocotrienol, it is preferably compounded in an amount of 5-5,000 mg per 1 kg of the feed. The content of cholesterol in a poultry egg, and the contents of triglycerides in an egg and/or plasma of poultry are preferably reduced.
The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 27mg. The duration of PCA analgesia was 48 hours.
Because all of the available non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) are metabolized by and affect hepatic cytochrome enzymes, combinations of two or more of these drugs produce complex pharmacokinetic (PK) interactions. However, little data exist regarding PK of anti-HIV drug combinations in the pediatric population. The purpose of this study is to assess steady-state PK of the following anti-HIV regimens: TDF and EFV or NVP; TDF and DRV with or without EFV; and TDF and RTV with or without EFV. In addition, this study will evaluate how age, length of treatment, adverse effects, and genes affect children's response to different anti-HIV combinations.

This study will last between 1 and 7 weeks. Participants in this study will be grouped based on the treatment regimen they are receiving or about to initiate. There are three groups in this study. Group D participants will receive TDF and EFV or NVP; Group E participants will receive TDF and DRV with or without EFV; and Group F participants will receive TDF and RTV with or without EFV. The inclusion of EFV or NVP will be dependent on each participant's prescribed regimen. Participants within each group will be stratified by age and how long they have been receiving their anti-HIV regimens. Antiretrovirals will not be provided by this study.

Most participants will have two study visits. The first visit will occur at study entry. Medical history, a physical exam, and blood collection will occur. The second visit will occur within 35 days of study entry and will take approximately 24 hours. Blood collection for PK studies, a physical exam, and medical history will be done at this visit. Urine collection will occur at all visits for female participants.

Participants will undergo PK testing at least 14 days after initiating their study regimens. Participants will be given a dose of their anti-HIV medications with food. A blood sample will be taken before dosing. Blood samples will also be taken at 1, 2, 4, 6, 8, 12, and 24 hours after dosing. Participants in Groups E and F may need to repeat PK testing within 6 weeks of initial PK testing at the discretion of the investigator.
The invention belongs to the technical field of biological medicine, and particularly relates to a collagen binding domain fusion CCL14 recombinant protein and application thereof. The amino acid sequence of the recombinant protein is shown as SEQ ID NO.1, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 2. The chemokine CCL14 is innovatively applied to tumor immunotherapy. Compared with the pure CCL14 protein, the mice are treated by the recombinant protein, so that the weight of the tumor is lighter and the tumor volume is smaller. Thus, the use of collagen binding domain fusion CCL14 recombinant proteins for immunotherapy of tumors is a viable, innovative, scientific solution.
PURPOSE: A method of preparing an activated copolymer and conjugates thereof capable of effectively delivering an activated non-antigenic biocompatible copolymer of polyethyleneimine and other biocompatible copolymers to a living body is provided. Therefore, the activated conjugates have a high delivery efficiency of a biological substance. CONSTITUTION: A biocompatible non-antigenic polymer is represented by the formula(I). In formula, PEI is polyethyleneimine, x and y are each an integer, P is a biocompatible non-antigenic polymer, A is a reactive functional group or methoxy(CH3O-). The PEI is a pure polyethyleneimine in which a primary, secondary and tertiary amine groups are present in a ratio of about 1:2:1 and have a number average molecular weight of about 500 to 20,000. The biologically active non-antigenic conjugates are represented by the formula(IIa, IIb or IIc). In formula, PEI is polyethyleneimine, x and y are each an integer, P is a biocompatible non-antigenic polymer and R is a biologically active substance.
OBJECTIVE: To independently validate the negative predictive value of the Tanta University risk model for intensive care requirements in poison center telephone consultations with other physicians.
METHODS: This study included 400 consecutive patients with acute poisoning. Clinical and laboratory parameters were recorded during the initial consultation with the poison center. Patients who were already ventilated or on vasopressors at the time of consultation were excluded. The Tanta University risk model score was calculated from the data according to the following equation: Tanta University risk model score = 1.966*Glasgow Coma Scale + 0.329*oxygen saturation (percent) + 0.212*diastolic blood pressure (mmHg) - 0.27*respiratory rate (breaths/minute) + 0.33*standard bicarbonate (mmol/L). Twenty-four hours later, the patients' courses were followed up by telephone. The Tanta University risk model was then compared to a composite endpoint indicating the requirement for admission to an intensive care unit (vasopressors, need for intubation, or death).
RESULTS: Four hundred patients with acute poisoning were included. Thirty-seven patients had a complicated clinical course as defined by the composite endpoint. Receiver operating characteristic analysis revealed the area under the curve to be 0.87 (95 percent confidence interval 0.83-0.90). An unfavorable Tanta University risk model score was defined as less than 73.46, using a cut-off derived from a previous study of an unrelated series of patients with acute poisoning admitted to our service. Thirty-one of 37 patients with complicated courses had an unfavorable Tanta University risk model score compared to six patients with complicated courses among 306 patients with a favorable Tanta University risk model score (P < 0.0002, Fisher's exact test). Sixty-three patients had an unfavorable Tanta University risk model score but an uneventful course. The negative predictive value of the Tanta University risk model was 0.98 (95 percent confidence interval 0.96-0.99), sensitivity was 0.84, and specificity 0.83.
CONCLUSIONS: In the present study of poison center telephone consultations, the Tanta University risk model was significantly related to the outcomes in patients with acute poisoning. Patients with a favorable Tanta University risk model score (greater than or equal to 73.46) were unlikely to need intensive care unit level of care.
Sodium Phenylbutyrate Tablets, USP for oral administration contain sodium phenylbutyrate, USP. Sodium phenylbutyrate is a white to yellowish-white powder which is freely soluble in water and has a strong salty taste. Sodium phenylbutyrate also is freely soluble in methanol, sparingly soluble in ethanol and practically insoluble in methylene chloride, acetone and diethyl ether. It is known chemically as 4-phenylbutyric acid, sodium salt with a molecular weight of 186.18 g/mol and the molecular formula C10H11O2Na.

Chemical Structure:

Each tablet of sodium phenylbutyrate tablets, USP contains 500 mg of sodium phenylbutyrate, USP and the inactive ingredients calcium stearate, colloidal silicon dioxide, magnesium stearate and microcrystalline cellulose. 

FDA approved dissolution specifications differs from the USP.
The invention discloses a small molecule peptide, the amino acid sequence of which is IIPFIF as shown in SEQ ID NO. 2. The application of the small molecular peptide in preparing medicaments or health-care products with tyrosinase inhibition effect. A medicine or health product with tyrosinase inhibiting activity contains the small molecular peptide as effective component. The invention also provides a royal jelly polypeptide with tyrosinase inhibitory activity, which is obtained by enzymolysis of royal jelly by using acid protease. According to the invention, through experimental research, the small molecular peptide with high inhibition activity on tyrosinase is obtained through screening, and the small molecular peptide has potential as a functional product for inhibiting melanin level.
This is a pilot study to determine whether light treatment can improve glucose metabolism in people with prediabetes. Individuals will be asked to complete a baseline session with one-week of at-home sleep monitoring followed by a 24-hour stay in the clinical research unit. During this stay, we will sample saliva in the evening to measure melatonin to estimate the timing of the internal biological clock ("circadian phase") and then we will perform a 3-hour oral glucose tolerance test in the morning to estimate markers of glucose metabolism, including insulin sensitivity. The participants will then be given a light device and instructed on its use. They will use the device for four weeks and visit our laboratory every week for a check-in. At the end of the four weeks, they will repeat the 24-hour stay in the clinical research unit.